Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program

被引:291
作者
Morgan, J
Wannemuehler, KA
Marr, KA
Hadley, S
Kontoyiannis, DP
Walsh, TJ
Fridkin, SK
Pappas, PG
Warnock, DW
机构
[1] Ctr Dis Control & Prevent, Mycot Dis Branch, Atlanta, GA 30333 USA
[2] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
[3] Tufts New England Med Ctr, Boston, MA USA
[4] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
[5] NCI, Bethesda, MD 20892 USA
[6] Univ Alabama, Birmingham, AL USA
关键词
aspergillosis; incidence; surveillance; transplantation;
D O I
10.1080/13693780400020113
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The incidence of invasive aspergillosis was estimated among 4621 hematopoietic stem cell transplants (HSCT) and 4110 solid organ transplants (SOT) at 19 sites dispersed throughout the United States, during a 22 month period from I March 2001 through 31 December 2002. Cases were identified using the consensus definitions for proven and probable infection developed by the Invasive Fungal Infections Cooperative Group of the European Organization for Research and Treatment of Cancer and the Mycoses Study Group of the National Institute of Allergy and Infectious Diseases. The cumulative incidence (CI) of aspergillosis was calculated for the first episode of the infection that occurred within the specified time period after transplantation. To obtain an aggregate CI for each type of transplant, data from participating sites were weighted according to the proportion of transplants followed-up for specified time periods (four and 12 months for HSCT; six and 12 months for SOT). The aggregate CI of aspergillosis at 12 months was 0.5% after autologous HSCT, 2.3% after allogeneic HSCT from an HLA-matched related donor, 3.2% after transplantation from an HLA-mismatched related donor, and 3.9% after transplantation from an unrelated donor. The aggregate Cl at 12 months was similar following myeloablative or non-myeloablative conditioning before allogeneic HSCT (3.1 vs. 3.3%). After HSCT, mortality at 3 months following diagnosis of aspergillosis ranged from 53.8% of autologous transplants to 84.6% of unrelated-donor transplants. The aggregate CI of aspergillosis at 12 months was 2.4% after lung transplantation, 0.8% after heart transplantation, 0.3% after liver transplantation, and 0.1% after kidney transplantation. After SOT, mortality at three months after diagnosis of aspergillosis ranged from 20% for lung transplants to 66.7% for heart and kidney transplants. The Aspergillus spp. associated with infections after HSCT included A. fumigatus (56%), A. flavus (18.7%), A. terreus (16%), A. niger (8%), and A. versicolor (1.3%). Those associated with infections after SOT included A. fumigatus (76.4%), A. flavus (11.8%), and A. terreus (11.8%). In conclusion, we found that invasive aspergillosis is an uncommon complication of HSCT and SOT, but one that continues to be associated with poor outcomes. Our CI figures are lower compared to those of previous reports. The reasons for this are unclear, but may be related to changes in transplantation practices, diagnostic methods, and supportive care.
引用
收藏
页码:S49 / S58
页数:10
相关论文
共 27 条
[11]   Incidence and risk factors for invasive fungal infections in allogeneic BMT recipients [J].
Jantunen, E ;
Ruutu, P ;
Niskanen, L ;
Volin, L ;
Parkkali, T ;
KoukilaKahkola, P ;
Ruutu, T .
BONE MARROW TRANSPLANTATION, 1997, 19 (08) :801-808
[12]  
Kalbleisch JD, 1980, STAT ANAL FAILURE TI
[13]   Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors [J].
Marr, KA ;
Carter, RA ;
Boeckh, M ;
Martin, P ;
Corey, L .
BLOOD, 2002, 100 (13) :4358-4366
[14]   Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients [J].
Marr, KA ;
Carter, RA ;
Crippa, F ;
Wald, A ;
Corey, L .
CLINICAL INFECTIOUS DISEASES, 2002, 34 (07) :909-917
[15]   Invasive fungal infections after allogeneic peripheral blood stem cell transplantation:: incidence and risk factors in 395 patients [J].
Martino, R ;
Subirá, M ;
Rovira, M ;
Solano, C ;
Vázquez, L ;
Sanz, GF ;
Urbano-Ispizua, A ;
Brunet, S ;
De la Cámara, R .
BRITISH JOURNAL OF HAEMATOLOGY, 2002, 116 (02) :475-482
[16]  
Minari A, 2002, Transpl Infect Dis, V4, P195, DOI 10.1034/j.1399-3062.2002.t01-2-02002.x
[17]   High rate of secondary viral and bacterial infections in patients undergoing allogeneic bone marrow mini-transplantation [J].
Mohty, M ;
Faucher, C ;
Vey, N ;
Stoppa, AM ;
Viret, F ;
Chabbert, I ;
Chabannon, C ;
Bouabdallah, R ;
Ladaique, P ;
Collet, L ;
Zandotti, C ;
Maraninchi, D ;
Baise, D .
BONE MARROW TRANSPLANTATION, 2000, 26 (03) :251-255
[18]   Invasive aspergillosis in the setting of cardiac transplantation [J].
Montoya, JG ;
Chaparro, SV ;
Celis, D ;
Cortés, JA ;
Leung, AN ;
Robbins, RC ;
Stevens, DA .
CLINICAL INFECTIOUS DISEASES, 2003, 37 :S281-S292
[19]   Infectious complications among 620 consecutive heart transplant patients at Stanford University Medical Center [J].
Montoya, JG ;
Giraldo, LF ;
Efron, B ;
Stinson, EB ;
Gamberg, P ;
Hung, S ;
Giannetti, N ;
Miller, J ;
Remington, JS .
CLINICAL INFECTIOUS DISEASES, 2001, 33 (05) :629-640
[20]   Infectious complications within the first year after nonmyeloablative allogeneic peripheral blood stem cell transplantation [J].
Mossad, SB ;
Avery, RK ;
Longworth, DL ;
Kuczkowski, EM ;
McBee, M ;
Pohlman, BL ;
Sobecks, RM ;
Kalaycio, ME ;
Andresen, SW ;
Macklis, RM ;
Bolwell, BJ .
BONE MARROW TRANSPLANTATION, 2001, 28 (05) :491-495